Röllig, C., Serve, H., Hüttmann, A., Noppeney, R., Müller-Tidow, C., Krug, U., . . . Ehninger, G. (2015). Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): A multicentre, phase 2, randomised controlled trial. The lancet. Oncology, 16(16), . https://doi.org/10.1016/S1470-2045(15)00362-9
Chicago-Zitierstil (17. Ausg.)Röllig, Christoph, et al. "Addition of Sorafenib Versus Placebo to Standard Therapy in Patients Aged 60 Years or Younger with Newly Diagnosed Acute Myeloid Leukaemia (SORAML): A Multicentre, Phase 2, Randomised Controlled Trial." The Lancet. Oncology 16, no. 16 (2015). https://doi.org/10.1016/S1470-2045(15)00362-9.
MLA-Zitierstil (9. Ausg.)Röllig, Christoph, et al. "Addition of Sorafenib Versus Placebo to Standard Therapy in Patients Aged 60 Years or Younger with Newly Diagnosed Acute Myeloid Leukaemia (SORAML): A Multicentre, Phase 2, Randomised Controlled Trial." The Lancet. Oncology, vol. 16, no. 16, 2015, https://doi.org/10.1016/S1470-2045(15)00362-9.